For example, in a nested case–control analysis of patients with type 2 diabetes receiving drug treatment, the treatment of GLP-1R agonists increased the risk of medullary thyroid cancer and thyroid cancer [189]. Here, GLP1R is linked to type 2 diabetes mellitus.